Rosuvastatin 10 mg. daily for 96 weeks + Placebo
Phase 2Completed 0 views this week 0 watching💤 Quiet
Interest: 35/100
35
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
HIV Infections
Conditions
HIV Infections, Heart Disease
Trial Timeline
Feb 1, 2011 → May 1, 2014
NCT ID
NCT01218802About Rosuvastatin 10 mg. daily for 96 weeks + Placebo
Rosuvastatin 10 mg. daily for 96 weeks + Placebo is a phase 2 stage product being developed by AstraZeneca for HIV Infections. The current trial status is completed. This product is registered under clinical trial identifier NCT01218802. Target conditions include HIV Infections, Heart Disease.
What happened to similar drugs?
20 of 20 similar drugs in HIV Infections were approved
Approved (20) Terminated (3) Active (0)
Hype Score Breakdown
Clinical
12
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01218802 | Phase 2 | Completed |
Competing Products
20 competing products in HIV Infections